The global Veterinary Diagnostics Market, valued at US$3.42 billion in 2024, increased to US$3.68 billion in 2025 and is set to grow at a resilient CAGR of 7.8% from 2025 to 2030, ultimately reaching US$5.36 billion by 2030. The market is undergoing a rapid transformation driven by breakthroughs in diagnostic technologies, rising companion animal ownership, and increasing global focus on zoonotic disease surveillance. As veterinary care shifts toward precision diagnostics and decentralized testing, the sector is becoming a critical enabler of modern animal health, preventive medicine, and livestock health management.
Market Dynamics: Technology, Pet Health Awareness, and Zoonotic Disease Surveillance Fuel Growth
Three major forces are reshaping the veterinary diagnostics landscape:
- Surge in Advanced Diagnostic Technologies
The market is witnessing accelerated adoption of:
- Point-of-care (POC) testing devices
- Molecular diagnostics, including PCR, qPCR, and LAMP assays
- AI-driven interpretation tools and digital pathology
These solutions improve clinical decision-making by enabling faster, more accurate diagnostics with minimal sample preparation. AI-based image analysis, cloud-based reporting, and integrated diagnostic platforms are reducing turnaround times and advancing real-time, patient-side decision support.
- Rising Incidence of Companion Animal Diseases
Demand for diagnostics related to diabetes, kidney disorders, infectious diseases, and vector-borne illnesses is growing sharply. Companion animals—especially dogs and cats—are receiving more preventive, routine, and chronic disease management care than ever before due to increased pet ownership and rising household spending on pet health.
- Growing Focus on Zoonoses and Livestock Disease Control
With over 60% of emerging infectious diseases being zoonotic, governments and agencies worldwide are investing heavily in surveillance programs. Strengthened disease monitoring in livestock, enhanced farm-level testing, and improved food safety regulations are expanding the adoption of molecular diagnostics and high-throughput testing systems.
Market Segmentation: Companion Animals and POC Testing Lead the Growth Curve
By Animal Type: Companion Animals Dominate Market Share
The market is segmented into:
- Companion Animals
- Livestock Animals
Companion animals accounted for the largest share in 2024, supported by:
- Increasing adoption of pets globally
- Higher emotional attachment and willingness to invest in premium veterinary care
- Growing awareness of early disease detection
- Availability of advanced diagnostic tests in clinics
As chronic diseases in pets rise, diagnostic intensity and frequency per patient continue to grow.
By End User: POC/In-House Testing to Register the Fastest CAGR
Key end-user segments include:
- Veterinary reference laboratories
- Veterinary hospitals & clinics
- Point-of-care/In-house testing (fastest-growing)
- Veterinary research institutes & universities
POC diagnostics are gaining traction as practices seek:
- Lower cost of testing
- Faster turnaround times
- Improved patient workflow
- Decentralized access to critical testing modalities
Technological innovations are enabling more tests—once limited to centralized labs—to move toward near-patient settings, making diagnostics more accessible to small and mid-size veterinary practices and even livestock farms.
Regional Insights: Asia Pacific Emerges as the Fastest-Growing Market
While North America and Europe remain mature markets, the Asia Pacific region is projected to register the fastest CAGR between 2025 and 2030.
Growth drivers include:
- Rapid urbanization and rising middle-class disposable incomes
- Expanding pet ownership in China, India, South Korea, and Southeast Asia
- Strengthening livestock health monitoring systems
- Government-led initiatives in food safety and zoonotic disease prevention
- Increased presence of multinational diagnostic companies
- Large-scale investments in veterinary hospitals, imaging centers, and diagnostic labs
The region’s growing attention to animal health and food chain safety positions it as a key strategic growth hub for diagnostics manufacturers.
Competitive Landscape: Innovation, AI Integration, and Molecular Diagnostics Define Leadership
The veterinary diagnostics market is moderately consolidated, with leading players focusing on product innovation, AI-driven tools, digital platforms, and expansion of molecular testing portfolios. Prominent companies include:
- IDEXX Laboratories, Inc. (US) — Global Leader in Companion Animal Diagnostics
IDEXX dominates the companion animal diagnostics market with a comprehensive ecosystem of analyzers, rapid tests, digital imaging, and cloud-enabled platforms. Key offerings include:
- Catalyst One (chemistry analyzer)
- ProCyte Dx (hematology)
- SNAP rapid immunoassay tests
- VetConnect PLUS (cloud-based results & analytics)
- VETLAB Station for integrated diagnostics
Recent innovations include Cystatin B, a breakthrough biomarker launched in 2023 for early detection of kidney injury in cats and dogs. IDEXX also continues to expand Vetscan Imagyst, powered by AI, supporting cytology, fecal analysis, and dermatology diagnostics.
The company reinvests over 6% of its annual revenue into R&D, driving precision diagnostics and seamless digital workflows for veterinary practices.
- Zoetis Services LLC (US) — Broad Portfolio Across Companion Animals & Livestock
Zoetis continues to build one of the most comprehensive diagnostic platforms in the industry, with strong presence in POC testing:
Key products include:
- VETSCAN VS2
- VETSCAN Imagyst (AI-based cytology & fecal analysis)
- VETSCAN SA (hematology)
Recent launches strengthening the portfolio:
- VETSCAN OptiCell (2024): AI-enabled hematology analyzer generating CBC results in under 5 minutes
- AI Urine Sediment Analysis (2024 update to Imagyst platform)
- AI Masses (2025 launch): AI-powered tool to enhance oncology & cytology diagnostics
Zoetis continues investing significantly in AI, data integration, and biomarker-based tests to expand the diagnostic capabilities of its digital platforms.
- Thermo Fisher Scientific Inc. (US) — Leader in Molecular & Biosecurity Diagnostics
Thermo Fisher delivers high-precision molecular diagnostics for livestock and zoonotic disease surveillance, strengthening global disease control efforts.
Key offerings include:
- VetMAX real-time PCR kits
- QuantStudio & Applied Biosystems PCR instruments
- Assays for major diseases such as avian influenza, BVD, and African swine fever
Thermo Fisher collaborates with government agencies, food safety authorities, and veterinary labs, enhancing global biosecurity capabilities. The company continuously invests in R&D to accelerate sample-to-answer turnaround times and develop high-sensitivity assays tailored to emerging pathogens.
Conclusion: Veterinary Diagnostics Enter a New Era of Precision, Speed, and Digital Transformation
The veterinary diagnostics market is evolving rapidly, fueled by technological innovation, rising pet healthcare expenditure, and growing global attention to zoonotic disease prevention. The shift toward AI-enabled diagnostics, molecular testing, and decentralized POC solutions is transforming the veterinary care ecosystem, enabling veterinarians, livestock producers, and researchers to make faster and more accurate clinical decisions.
As emerging markets accelerate their adoption of advanced diagnostics and global players expand their AI-driven platforms, the next five years will position veterinary diagnostics as a cornerstone of modern animal health management and global biosecurity.